GlassScriptPhysician profile
Julia E Disanti
NPI 1295259646
$3,089.32
in general payments reported to CMS, 2019-2025
28 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,414 · 2022: $1,087 · 2023: $313 · 2024: $87.84 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $459.42 | 2021-2023 | Shingrix, Bexsero, Trelegy Ellipta |
| Pfizer INC. | $369.36 | 2021-2023 | |
| Indivior INC. | $275.72 | 2024-2025 | Sublocade |
| Novo Nordisk INC | $267.60 | 2021-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.01 | 2021-2023 | Stiolto Respimat |
| Abbvie INC. | $209.31 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $153.86 | 2021-2023 | Eliquis |
| Lilly USA, LLC | $141.98 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $136.08 | 2021-2023 | Fasenra |
| Sanofi-Aventis U.S. LLC | $134.16 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $122.38 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.62 | 2021-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Amgen INC. | $79.95 | 2021-2023 | Repatha, Otezla |
| Abbott Laboratories | $70.16 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $67.64 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $48.36 | 2021 | |
| Dexcom, INC. | $36.69 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $31.62 | 2021 | |
| Nestle Healthcare Nutrition INC. | $28.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.81 | 2021-2022 | |
| Allergan, INC. | $24.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.34 | 2022 | |
| Sanofi Pasteur INC. | $16.11 | 2023 | |
| Edwards Lifesciences Corporation | $15.47 | 2022 | |
| Nevro Corp. | $14.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.10 | 2022 | |
| Horizon Therapeutics Plc | $13.41 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Disanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.